CORDIS
EU research results

CORDIS

English EN

News

A COMPOSITION OBTAINED FROM A PIGMENT BELONGING TO THE FAMILY OF ANTHOCYANINS FOR THE TREATMENT OF TYPE 1 DIABETES DISEASE / PART 2

The invention relates in particular to a composition, which is obtained from a pigment belonging to the family of anthocyanins and which features the ability to increase the insulin sensitivity and to trigger the insulin release. Part 2 of The Previous Article Erdal Can Alkoclar & Metehan Yesil

© Erdal Can Alkoclar & Metehan Yesil

We hereby continue to disclose the Anti - Diabetic and Insulinotrophic Formulation as the continuation of Article Part 1. Detailed Description of the Invention Gymnema sylvestre ayurvedic is a herb, which has been used for a long time in medicine in order to regulate sugar. Among the components naturally contained in Gymnema sylvestre, 28-hexahydroxy-olean-12-ene, 23-hexahydroxy-olean-12-ene, gymnemic acid IV trigger the regeneration of the beta cells in pancreas, which produce insulin. Ginsenoside rh2 is a tripertene saponin, which is naturally contained by the Ginseng plant in a low amount. In addition to being one of the strongest anti-cancer components, it also has a strong insulinotrophic (ability to trigger insulin release) feature resulting from its ability to increase the level of beta-endorphine. When said components are combined in a formulation and are used simultaneously, 28-hexahydroxy-olean-12-ene, 23-hexahydroxy-olean-12-ene and gymnemic acid IV, which are naturally contained in Gymnema sylvestre, trigger the regeneration of the beta cells in pancreas, while ginsenoside rh2 supports to the maximum extent the insulin release triggered by acetylcholine. Cyanidin-3-glucoside is a pigment belonging to the family of anthocyanins, which features the ability to increase the insulin sensitivity and to trigger the insulin release. This component, present in high proportions in currant and black grapes, has an insulinotrophic effect. It features the ability to suppress the cytokines like tnf-alpha, which are detrimental to beta cells. Thus, this component prevents the disruption of the repair process in the beta cells of the pancreas triggered by 28-hexahydroxy-olean-12-ene, 23-hexahydroxy-olean-12-ene and gymnemic acid IV. The formulation of the composition for the type 1 diabetes according to the invention comprises the components of 28-hexahydroxy-olean-12-ene, 23-hexahydroxy-olean-12-ene, gymnemic acid IV, ginsenoside Rh2 and cyanidin-3-glucoside. Said formulation is obtained by mixing the aforementioned components according to the following ratios by weight: 5-10% of 28-hexahydroxy-olean-12-ene, 5-10% of 23-hexahydroxy-olean-12-ene, 40-65% of gymnemic acid IV, 5-10% of ginsenoside Rh2, 20-30% of cyanidin-3-glucoside. The components given above are obtained by the components selected from the aforementioned group, used alone or joined in the form of combinations according to the weight ratio ranges provided above. CLAIMS 1. The invention is a composition for the treatment of type 1 diabetes disease, said composition being obtained by combining, individually or in combinations, the components selected from the group comprising 28-hexahydroxy-olean-12-ene, 23-hexahydroxy-olean-12-ene, gymnemic acid IV, ginsenoside Rh2 and cyanidin-3-glucoside. 2. A composition according to Claim 1 characterized in that it comprises 28-hexahydroxy-olean-12-ene at a ratio of 5-10%. 3. A composition according to Claim 1 characterized in that it comprises 23-hexahydroxy-olean-12-ene at a ratio of 5-10%. 4. A composition according to Claim 1 characterized in that it comprises gymnemic acid IV at a ratio of 40-65%. 5. A composition according to Claim 1 characterized in that it comprises ginsenoside Rh2 at a ratio of 5-10%. 6. A composition according to Claim 1 characterized in that it comprises cyanidin-3-glucoside at a ratio of 20-30%. 7. The invention is the use of the composition according to Claims 1 to 6 for the treatment of the type 1 diabetes disease. 8. The invention is the manufacture of the composition according to Claims 1 to 6 used for the treatment of the type 1 diabetes disease. Above-mentioned compounds exert a promising and synergistic anti-diabetic and insulinotrophic effect for the sufferers from this autoimmune ailment. We sincerely hope this may serve as a potential treatment for Type 1 Diabetes. Best Regards Erdal Can Alkoclar & Metehan Yesil

Contributor

Contributed by:

Mas Pharmaceuticals

Turkey

Contact

Erdal Can Alkoclar (Mr)

See more articles from this contributor